Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

REAL-WORLD CLINICAL OUTCOMES AMONG PATIENTS INCLUDED IN AN EARLY ACCESS PROGRAMME TREATED WITH DURVALUMAB IN COMBINATION WITH PLATINUM AND ETOPOSIDE AS FIRST-LINE THERAPY IN EXTENSIVE-STAGE SMALL CELL LUNG CANCER: AN ITALIAN MULTICENTER OBSERVATIONAL STUDY

NCT06826677 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.

NCT NCT06826677
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06826677 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
REAL-WORLD CLINICAL OUTCOMES AMONG PATIENTS INCLUDED IN AN EARLY ACCESS PROGRAMME TREATED WITH DURVALUMAB IN COMBINATION WITH PLATINUM AND ETOPOSIDE AS FIRST-LINE THERAPY IN EXTENSIVE-STAGE SMALL CELL LUNG CANCER: AN ITALIAN MULTICENTER OBSERVATIONAL STUDY
Lead sponsor
AstraZeneca
Phase
Observational
Overall status
Completed
Start date
July 30, 2024
Completion date
January 23, 2025
Enrollment
71 (actual)
Sites
11

Conditions

As the registry lists them; a condition with its own page is linked.

small cell lung carcinoma